Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (HO170DLBCL)

ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial

Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corresponds to a cumulative incidence of 5-10% within 5-years after receiving R-CHOP. In the elderly, an incidence of 26% has been reported after 8-years of follow-up. Among patients who die in complete remission, heart failure has been described to be one of the most important causes of death. ANTICIPATE aims to evaluate if dexrazoxane can prevent AICD in DLBCL patients and identify those at highest risk of AICD. Of all patients treated with anthracyclines in a first-line setting, DLBCL patients were chosen for this trial for two primary reasons. Firstly, these patients have a favourable oncological prognosis with a 5-year relative survival in the Netherlands of 64-78% in those aged 18-74 years increasing the importance of preventing long-term toxicity. Secondly, the cumulative anthracycline dose used for the treatment of DLBCL is higher than the dose used in breast cancer. The cumulative anthracycline dose is the most important risk factor for AICD known.

Study Overview

• Status: Not yet recruiting
• Conditions: DLBCL - Diffuse Large B Cell Lymphoma
• Intervention / Treatment: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisolone; Drug: Lenalidomide; Drug: Dexrazoxane; Drug: Pegfilgrastim

Detailed Description

HO170 DLBCL-ANTICIPATE: "Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell lymphoma" is a national randomized controlled trial that will be conducted across 25 Dutch hospitals. This study will include adult patients with DLBCL in which first-line treatment with 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is planned (cumulative doxorubicin dose 300 mg/m2). In this trial, we have chosen to include patients with a normal cardiac function before chemotherapy because cardiac dysfunction is a contra-indication for administration of anthracyclines. A total of 324 DLBCL patients will prior to treatment be randomized in a 1:1 ratio to either (1) intravenous dexrazoxane administration in a 10:1 dexrazoxane:doxorubicin ratio prior to each doxorubicin infusion or (2) no cardioprotective treatment (current standard of care). Due to the low pH of the dexrazoxane solution that would jeopardize the blinding no placebo is used. Cardiac function will be screened with echocardiography prior to the initiation of chemotherapy and followed-up at 4- and 12-months post randomization. The primary end point of the study will be the incidence of AICD, defined as a left ventricular ejection fraction (LVEF) decline of ≥10 percentage points from baseline and below 50% (normal reference value for two-dimensional (2D) echocardiography). The secondary endpoint will be the percentage of patients with complete metabolic remission (CMR) after R-CHOP chemotherapy, to reassure that dexrazoxane does not influence the antineoplastic efficacy of doxorubicin. To declare ANTICIPATE successful, the trial must show both the superiority of addition of dexrazoxane on the primary endpoint and non-inferiority on the secondary endpoint. Deep-phenotyping of patient- and treatment-related factors will be performed to evaluate their prognostic value.

• Study Type: Interventional
• Enrollment (Estimated): 324
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: A. van Rhenen, MD; Phone Number: +31 107041560; Email: A.vanRhenen@umcutrecht.nl
• Study Contact Backup: Name: M.P.M. Linschoten, MD; Email: m.p.m.linschoten@amsterdamumc.nl

Study Locations

• Netherlands
  • Almelo, Netherlands
    • NL-Almelo-ZGTALMELO
  • Amstelveen, Netherlands
    • NL-Amstelveen-AMSTELLAND
  • Apeldoorn, Netherlands
    • NL-Apeldoorn-GELREAPELDOORN
  • Arnhem, Netherlands
    • NL-Arnhem-RIJNSTATE
  • Breda, Netherlands
    • NL-Breda-AMPHIA
  • Delft, Netherlands
    • NL-Delft-RDGG
  • Den Bosch, Netherlands
    • NL-Den Bosch-JBZ
  • Den Haag, Netherlands
    • NL-Den Haag-HAGA
  • Dordrecht, Netherlands
    • NL-Dordrecht-ASZ
  • Eindhoven, Netherlands
    • NL-Eindhoven-CATHARINA
  • Eindhoven, Netherlands
    • NL-Eindhoven-MAXIMAMC
  • Goes, Netherlands
    • NL-Goes-ADRZ
  • Groningen, Netherlands
    • NL-Groningen-MARTINI
  • Harderwijk, Netherlands
    • NL-Harderwijk-STJANSDALHARDERWIJK
  • Hilversum, Netherlands
    • NL-Hilversum-TERGOOI
  • Hoofddorp, Netherlands
    • NL-Hoofddorp-SPAARNEGASTHUIS
  • Nieuwegein, Netherlands
    • NL-Nieuwegein-ANTONIUS
  • Nijmegen, Netherlands
    • NL-Nijmegen-CWZ
  • Rotterdam, Netherlands
    • NL-Rotterdam-IKAZIA
  • Schiedam, Netherlands
    • NL-Schiedam-FRANCISCUSVLIETLAND
  • Sneek, Netherlands
    • NL-Sneek-ANTONIUSSNEEK
  • Utrecht, Netherlands
    • NL-Utrecht-UMCUTRECHT
  • Venlo, Netherlands
    • NL-Venlo-VIECURI
  • Zwolle, Netherlands
    • NL-Zwolle-ISALA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Untreated patients with a confirmed histologic diagnosis of CD20+ DLBCL according to WHO classification 2022:

   • DLBCL, not otherwise specified (NOS)
   • High-grade B-cell lymphoma NOS
   • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocation when DA-EPOCH-R is not an option. R2- CHOP is allowed.
   • Follicular lymphoma
   • T-cell/histiocyte-rich B cell lymphoma (THRBCL)

   Note: Transformed, previously untreated lymphoma is allowed.

   Note: 5-day treatment of dexamethasone 15 mg/day or prednisone 100 mg/day or local radiotherapy in order to control life-threatening/invalidating tumor related symptoms is allowed.

   Note: It is allowed to start with a first cycle of R-CHOP21 pending the FISH results.

2. Planned treatment with 6 R-CHOP21. The following regimens are also allowed:

   • Treatment with reversed R-CHOP21
   • Treatment with R2-CHOP21 (6 R-CHOP21 + lenalidomide 15 mg day 1-14) in case of double hit lymphoma
   • Two additional administrations of rituximab after 6 cycles of R-CHOP21
   • High dosis MTX and/or MTX-it for CNS prophylaxis
3. Ann Abor stages II-IV and stage I if the treatment plan is 6 R-CHOP21 in case of bulky disease (defined as a ≥10 cm mass);
4. Age ≥ 18 years;
5. WHO performance status ≤ 2, WHO 3 performance status is allowed when considered directly related to the DLBCL;
6. Negative pregnancy test at study entry for women of childbearing potential;
7. Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agrees to practice two effective methods of contraception, at the same time, from the time of signing the informed consent through at least 12 months after the last dose of protocol treatment, or agrees to completely abstain from heterosexual intercourse;
8. Male patient, even if surgically sterilized, (i.e., status post vasectomy) agrees to practice effective barrier contraception during the entire study period and through 12 months after the last dose of protocol treatment, or agrees to completely abstain from heterosexual intercourse;
9. Patient is able to adhere to the study visit schedule and other protocol requirements;
10. Written informed consent.

Exclusion Criteria:

1. Any of the following B-cell lymphomas according to WHO classification 2022:

   o Central Nervous System involvement by DLBCL;

   Note: high CNS-IPI is allowed

   • Testicular DLBCL;
   • Primary mediastinal B-cell lymphoma;
   • Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder;
2. Any prior malignancy or present malignancy other than DLBCL that required or requires systemic therapy. Prior surgery or local radiotherapy is allowed in case the heart has not been exposed.
3. Patients requiring treatment with mini-R-CHOP

4. Pre-existing cardiac disease including:

   • LVEF <50% measured with echocardiography (2D or 3D)
   • Symptomatic heart failure (NYHA ≥II) or hospitalization for heart failure in the last year;
   • Refractory anginal symptoms
   • Cardiac arrhythmias not controlled with optimal medical treatment, in case of atrial fibrillation the ventricular response needs to be <110/min;
   • Significant valvular dysfunction on echocardiography;
   • Non-ischemic cardiomyopathy
5. Non-diagnostic/poor transthoracic echocardiography imaging quality at baseline;
6. Severe pulmonary dysfunction defined as breathlessness at rest (COPD GOLD III or IV), unless clearly related to DLBCL;
7. Severe neurological or psychiatric disease;
8. Inadequate hematological function (absolute Neutrophil Count (ANC) <1.0x109/L or platelets <75x109/L), unless clearly related to DLBCL;
9. Significant hepatic dysfunction (serum bilirubin or transaminases ≥ 3 times the upper limit of normal) unless related to lymphoma infiltration of the liver;
10. Active hepatitis B or C infection (serology testing is required at screening). Patients positive for hepatitis B surface antigen (HBsAg) regardless of antibody status or HBsAg negative but anti-HBc positive are only eligible if HBV-PCR is negative and patients are protected with lamuvidine or entecavir. Patients with positive hepatitis C serology are only eligible if HCV-(RNA) is confirmed negative;
11. Significant renal dysfunction (creatinine clearance < 30 ml/min after rehydration) or requiring dialysis;
12. Active uncontrolled fungal, bacterial and/or viral infection;
13. Patient known to be HIV-positive;
14. Breast-feeding female patients;
15. Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
16. Participation in another clinical trial with anti-cancer therapy or a cardiovascular drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A; Standard R-CHOP 21 treatment regimen: 6 cycles R-CHOP 21 (rituximab*, cyclophosphamide, doxorubicin, vincristine, prednisolone) *The use of a biosimilar is allowed.	Drug: Rituximab; Day 1 Cycle 1-6: 375 mg/m2 (iv); Drug: Cyclophosphamide; Day 1 Cycle 1-6: 750 mg/m2 (iv); Drug: Doxorubicin; Day 1 Cycle 1-6: 50 mg/m2 (iv); Drug: Vincristine; Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv); Drug: Prednisolone; Day 1-5 Cycle 1-6: 100 mg (oral); Drug: Lenalidomide; Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.; Other Names: Revlimid; Drug: Pegfilgrastim; 6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.; Other Names: Pegfilgastim
Experimental: Arm B -; Addition of the cardioprotectant dexrazoxane to the R-CHOP 21 regimen: R-CHOP21 (rituximab*, cyclophosphamide, doxorubicin, vincristine, prednisolone plus dexrazoxane). *The use of a biosimilar is allowed.	Drug: Rituximab; Day 1 Cycle 1-6: 375 mg/m2 (iv); Drug: Cyclophosphamide; Day 1 Cycle 1-6: 750 mg/m2 (iv); Drug: Doxorubicin; Day 1 Cycle 1-6: 50 mg/m2 (iv); Drug: Vincristine; Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv); Drug: Prednisolone; Day 1-5 Cycle 1-6: 100 mg (oral); Drug: Lenalidomide; Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.; Other Names: Revlimid; Drug: Dexrazoxane; Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.; Other Names: Cardioxane; Drug: Pegfilgrastim; 6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.; Other Names: Pegfilgastim

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of AICD.	The incidence of AICD (measured with 2D) within 12 months after registration.	12 months after LPI

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Metabolic Remission.	Complete metabolic remission (CMR) on 18F-FDG PET-CT at end of treatment 6-8 weeks after completion of 6x R-CHOP21.	12 months after LPI
Overall survival (OS).	Overall survival (OS) at 12-months.	12 months after LPI
Progression-free survival.	Progression-free survival (PFS) at 12-months.	12 months after LPI
LVEF and global longitudinal strain (GLS).	LVEF (2D and 3D) and global longitudinal strain (GLS) at end of treatment and 12-months after start of treatment.	12 months after LPI
NYHA.	NYHA functional class.	12 months after LPI
Cardiac biomarkers.	Release of cardiac biomarkers. At entry, after every cyle of R-CHOP, at EOT and FU. CK (if available); CK-MB (if available) & (hs)Troponin T/I (assay according to local practice).	12 months after LPI
Quality of Life.	To analyse the impact of the addition of dexrazoxane on QoL via validated questionaires such as QLQ-C30, NHL-HG29, PRO-CTCAE.	12 months after LPI

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and toxicity.	Safety and toxicity as defined by type, frequency and severity of adverse events as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	12 months after LPI
Secondary malignancies.	Incidence of secondary malignancies.	12 months after LPI
Major Adverse Cardiovascular Events.	Major Adverse Cardiovascular Events (MACE) at 1-, 2-, 5- and 10-years.	1- 2-, 5- and 10 years

Collaborators and Investigators

• Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
• Collaborators: UMC Utrecht; Amsterdam University Medical Centers; The Dutch Network for Cardiovascular Research (WCN)
• Investigators: Principal Investigator: A. van Rhenen, MD, UMC Utrecht; Principal Investigator: M.P.M. Linschoten, MD, Amsterdam UMC

Publications and helpful links

Helpful Links

• HOVON study website

Study record dates

Study Major Dates

• Study Start (Estimated): May 21, 2024
• Primary Completion (Estimated): December 15, 2028
• Study Completion (Estimated): December 15, 2028

Study Registration Dates

• First Submitted: January 11, 2024
• First Submitted That Met QC Criteria: January 22, 2024
• First Posted (Actual): January 23, 2024

Study Record Updates

• Last Update Posted (Estimated): February 9, 2024
• Last Update Submitted That Met QC Criteria: February 7, 2024
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: heart failure; cardiotoxicity; primary prevention; FL; R-CHOP; LVEF; diffuse large B-cell lymphoma; dexrazoxane; R2CHOP
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Protective Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Cardiotonic Agents; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antibiotics, Antineoplastic; Prednisolone; Cyclophosphamide; Lenalidomide; Rituximab; Doxorubicin; Vincristine; Dexrazoxane; Razoxane
• Other Study ID Numbers: HO170 DLBCL-ANTICIPATE; 2023-505377-32 (Other Identifier: EU CT number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the current publication policy the protocol and Statistical Analysis Plan (SAP) will be shared. The Principal Investigators can be contacted for IPD sharing after the publication of the study results. According to the 'HOVON Sample and/or Data request Form' the HOVON director; chair of the lymphoma working group, the study PI and Coordinating Investigator should approve data/sample sharing.
• IPD Sharing Time Frame: After the publication of primary endpoint analysis.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No